Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02386098 · ClinicalTrials.gov registry record · Phase 2
Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults
A Phase 2 study, sponsored by ViiV Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT02386098: Clinical Trial Phase 2 study, sponsored by ViiV Healthcare.
NCT02386098 is a Phase 2 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 86 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02386098, a Phase 2 study, was terminated before completion, sponsored by ViiV Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) \[with or without ritonavir (RTV)\] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.
Primary Outcome
Blood samples were collected for quantitative analysis of plasma HIV-1 RNA. Percentage of participants with plasma HIV-1 RNA \<40 c/mL at Week 24 was assessed using the Food and Drug Administration (FDA) snapshot algorithm which used the last on-treatment plasma HIV-1 RNA measurement, within an FDA-specified visit window (18 to 30 weeks), to determine response. Analysis was performed on the modified intent to treat (mITT) Population which comprised of all randomized participants who received atl
Interventions
- DRUG BMS-955176
- DRUG Dolutegravir (DTG)
- DRUG Atazanavir (ATV)
- DRUG Ritonavir (RTV)
- DRUG Tenofovir (TDF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2015-07-08 |
| Est. Completion | 2017-06-07 |
| Phase | Phase 2 |
Why NCT02386098 stopped before completion
NCT02386098 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 5 interventions - of which BMS-955176 is the first listed.
NCT02386098 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02386098 about?
NCT02386098 is a clinical study titled "Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults". The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) \[with or without ritonavir (RTV)\] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.
What is the current status of trial NCT02386098?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2015-07-08. Estimated completion is 2017-06-07.
What interventions are being tested in trial NCT02386098?
The interventions under investigation include: BMS-955176 (DRUG), Dolutegravir (DTG) (DRUG), Atazanavir (ATV) (DRUG), Ritonavir (RTV) (DRUG), Tenofovir (TDF) (DRUG).
Who is sponsoring clinical trial NCT02386098?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02386098's enrollment target sits among peer trials
86 812th of 2000 higher than 1,181 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI